Letermovir
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Letermovir |
| DrugBank ID | DB12070 |
| Brand Names (EU) | Prevymis |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.88% |
Approved Indication (EMA)
Prevymis is indicated for prophylaxis of cytomegalovirus (CMV) reactivation and disease in adult and paediatric patients weighing at least 5 kg who are CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT).Prevymis is indicated for prophylaxis of CMV disease in CMV-seronegative adult and paediatric patients weighing at least 40 kg who have received a kidney transplant from a CMV-seropositive donor [D+/R-].Prevymis is indicated for prophylaxis of cytomegalov
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | vulvovaginal candidiasis | 99.88% | DL |
| 2 | fungal infectious disease | 98.93% | DL |
| 3 | tinea nigra | 98.62% | DL |
| 4 | infectious bovine rhinotracheitis | 98.48% | DL |
| 5 | malignant catarrh | 98.48% | DL |
| 6 | anogenital human papillomavirus infection | 97.99% | DL |
| 7 | cytomegalovirus infection | 97.96% | DL |
| 8 | AIDS | 97.86% | DL |
| 9 | dermatophytosis | 97.66% | DL |
| 10 | piedra | 97.16% | DL |
| 11 | varicella zoster infection | 96.87% | DL |
| 12 | congenital human immunodeficiency virus | 96.86% | DL |
| 13 | AIDS related complex | 96.86% | DL |
| 14 | postmenopausal atrophic vaginitis | 96.46% | DL |
| 15 | vulvovaginitis | 96.08% | DL |
| 16 | roseolovirus infectious disease | 95.68% | DL |
| 17 | vulvitis | 95.57% | DL |
| 18 | mycotic corneal ulcer | 95.51% | DL |
| 19 | commissural lip fistula | 95.36% | DL |
| 20 | burning mouth syndrome | 95.30% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.